Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain

Arai M, Tokunaga Y, Takagi A, Tobita Y, Hirata Y, Ishida Y, TatenoC, Kohara M
PLoS One. 2013 Dec 16;8(12):e82527.

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-beta type I receptor

Sakata, K. Hara, M. Terada, T. Watanabe, N. Takaya, D. Yaguchi, S. Matsumoto, T. Matsuura, T. Shirouzu, M. Yokoyama, S. Yamaguchi, T. Miyazawa, K. Aizaki, H. Suzuki, T. Wakita, T. Imoto, M. Kojima, S.
Sci Rep. 2013 Nov 22;3:3243. doi: 10.1038/srep03243.

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M.
Gut. 2013 Sep;62(9):1340-6

Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection.

Nakagawa S, Hirata Y, Kameyama T, Tokunaga Y, Nishito Y, Hirabayashi K, Yano J, Ochiya T, Tateno C, Tanaka Y, Mizokami M, Tsukiyama-Kohara K, Inoue K, Yoshiba M, Takaoka A, Kohara M.
PLoS One. 2013;8(3):e59611.

Thromboxane A2 Synthase Inhibitors Prevent Production of Infectious Hepatitis C Virus in Mice with Humanized Livers.

Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, Hijikata M
Gastroenterology. 2013 Sep;145(3):658-67.e11.

A Serine Palmitoyltransferase Inhibitor Inhibits Hepatitis C Virus Replication in Human Hepatocytes.

Katsume A, Tokunaga Y, Hirata Y, Munakata T, Saito M, Hayashi H, Okamoto K, Ohmori Y, Kusanagi I, Fujiwara S, Tsukuda T, Aoki Y, Klumpp K, Tsukiyama-Kohara K, El-Gohary A, Sudoh M, Kohara M.
Gastroenterology. 2013 Oct;145(4):865-73.

Demonstration of hepatitis C virus RNA with in situ hybridization employing a locked nucleic Acid probe in humanized liver of infected chimeric mice and in needle-biopsied human liver.

Shiogama K, Inada K, Kohara M, Teramoto H, Mizutani Y, Onouchi T, Tsutsumi Y.
Int J Hepatol. 2013;2013:249535. doi: 10.1155/2013/249535. Epub 2013 Jun 18.

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.

Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K.
Gut. 2013 Jul;62(7):1055-61

Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice

Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T
Gastroenterology. 2013 Aug;145(2): 447-455.

Synthetic lipophilic antioxidant BO-653 suppresses HCV replication.

Yasui F, Sudoh M, Arai M, Kohara M.
J Med Virol. 2013 Feb;85(2):241-9.

Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.

Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T.
J Virol. 2012 Oct;86(19):10805-20.

An orally available, small-molecule interferon inhibits viral replication

Hideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, Hitoshi Yoshino, Hiroshi Ohmori, Motooki Ashihara, Yuichi Hirata, Atsunori Ohta, Hiroshi Sakamoto, Natsuko Hada, Asao Katsume, Michinori Kohara, Kazumi Morikawa, Takuo Tsukuda, Nobuo Shimma, Graham R. Foster, William Alazawi, Yuko Aoki, Mikio Arisawa & Masayuki Sudoh
Scientific Reports Volume: 2,Article number:259

Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.
Nat Med. 2012 Jan 8;18(2):281-5

Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice

Ype P. de Jong1,2, Charles M. Rice1, Alexander Ploss1,

J Hepatol.2011; 54:848–850

Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.

Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K.
Hepatology. 2011 Sep 2;54(3):764-71.

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.

Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.
Hepatology. 2011 Sep 2;54(3):781-8.

Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes.

Takano T, Tsukiyama-Kohara K, Hayashi M, Hirata Y, Satoh M, Tokunaga Y, Tateno C, Hayashi Y, Hishima T, Funata N, Sudo M, Kohara M.

J Hepatol. 2011 Sep;55(3):512-21

ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.

Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K.
J Hepatol. 2011 Jul;55(1):11-8. Epub 2010 Nov 29.

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKea
Nat Med. 2011 May;17(5):589-95.

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.

Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, Chayama K.
J Hepatol. 2011 May;54(5):872-8